Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

Written by Customer Service on May 19, 2021. Posted in Public Companies.

Study Is First to Validate New Polygenic Risk Assessment for All; Company Aims to Improve Access and Reduce Disparities in Genetic Testing SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study with more than 275,000 women validating the use of a new method for polygenic breast cancer risk assessments in women of all ancestries. The new data will be shared in an oral presentation with leading collaborators on June 4 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. “The polygenic risk score (PRS) is one of the most powerful risk prediction tools in the field of breast cancer, and until now a validated model had not been available to assess women of all ancestries,” said...

CF Energy Completed A Non-Brokered Private Placement Financing

Written by Customer Service on May 19, 2021. Posted in Public Companies.

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) — CF Energy Corp. (TSX-V: CFY) (“CF Energy” or the “Company”, together with its subsidiaries, the “Group”), a leading new energy service provider in the People’s Republic of China (the ”PRC” or “China”) is pleased to announce that the Company has completed a non-brokered private placement of unsecured convertible debentures in the aggregate principal amount of $600,000 CAD (the “Convertible Debenture”). The Convertible Debentures have a term of two years ending on May 19, 2023 (the “Maturity Date”) with 7% interest per annum to be paid semi-annually, with an option of the holders of the debenture (the “Debenture Holders”) to convert the principal amount outstanding under the Convertible Debenture into common shares of the Company (“Shares”) at a conversion price of $0.66 CAD (the “Conversion...

$Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021$

Oncternal Therapeutics Presents Updated Interim Data for TK216 in Patients with Relapsed or Refractory Ewing Sarcoma in an Oral Session at ASCO 2021

Written by Customer Service on May 19, 2021. Posted in Public Companies.

Latest data from study TK216-01 remain encouraging, are consistent with previous results, and are updated over data contained in ASCO Abstract #11500 released today Two patients who achieved a complete response (CR) remain with no evidence of disease, one for over 24 months and the other for over 14 months on study TK216 remained generally well tolerated with a manageable safety profile SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced updated interim clinical data from the oral presentation on its ongoing Phase 1/2 clinical trial evaluating TK216, an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family...

Parker Scheduled to Present at the Wolfe Research Global Transportation and Industrials Conference on May 26 at 1:00 p.m. Eastern

Written by Customer Service on May 19, 2021. Posted in Public Companies.

CLEVELAND, May 19, 2021 (GLOBE NEWSWIRE) — Parker Hannifin Corporation (NYSE: PH), the global leader in motion and control technologies, today announced that it is scheduled to present at the Wolfe Research Global Transportation and Industrials Conference being held virtually on Wednesday, May 26, 2021 at 1:00 p.m. Eastern time. Parker’s scheduled presenter is Tom Williams, Chairman and Chief Executive Officer. A live webcast of the presentation will be accessible on Parker’s investor information website at www.phstock.com and will be archived on the site. Parker Hannifin is a Fortune 250 global leader in motion and control technologies. For more than a century the company has been enabling engineering breakthroughs that lead to a better tomorrow. Parker has increased its annual dividend per share paid to shareholders...

Extended Stay America Files Investor Presentation in Support of Transaction with Blackstone and Starwood Capital

Written by Customer Service on May 19, 2021. Posted in Mergers And Acquisitions.

Urges Shareholders to Vote on June 8 “FOR” the Sale on the WHITE Company Proxy Card CHARLOTTE, N.C., May 19, 2021 (GLOBE NEWSWIRE) — Extended Stay America, Inc. (“ESA”) and its paired-share REIT, ESH Hospitality, Inc. (“ESH” and, together with ESA, “Extended Stay” or the “Company”) (NASDAQ: STAY) today filed an investor presentation with the Securities and Exchange Commission highlighting the immediate and compelling value the Company’s transaction with Blackstone and Starwood Capital will deliver to shareholders. The Special Meetings of Shareholders are scheduled for June 8, 2021. The presentation emphasizes the fact that the $19.50 per share all-cash transaction provides compelling value and captures the future upside inherent in the Company’s strategic plan. It also highlights four key points that investors should consider before...

Northland Power Reports on the 2021 Annual and Special Meeting

Written by Customer Service on May 19, 2021. Posted in Public Companies.

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) — Northland Power Inc. (“Northland” or the “Company”) (TSX: NPI) today announced the results of the election of Directors at its Annual and Special Meeting (“the Meeting”) held on May 19, 2021 in a virtual-only meeting format. The total number of voting shares represented by shareholders present electronically and by proxy at the Meeting was 126,732,525, representing 62.54% of Northland’s outstanding voting shares. The nine nominees proposed by Management for election as Directors, including the two new Directors, Kevin Glass and Helen Mallovy Hicks, were elected. Information on each of the Director Nominees is contained in Northland’s Management Information Circular dated April 14, 2021, which is available on the company’s website at www.northlandpower.com The votes received were as follows: Nominee Votes...

Oil States Wins Spotlight on New Technology® Award for Deepsea Mineral Riser System

Written by Customer Service on May 19, 2021. Posted in Public Companies.

HOUSTON, May 19, 2021 (GLOBE NEWSWIRE) — Oil States International, Inc. (NYSE: OIS) announced that it was presented with a Spotlight on New Technology® Award by the 2021 Offshore Technology Conference (OTC) for its Merlin™ Deepsea Mineral Riser System. The award recognizes Oil States for their technological advances in support of the developing deepsea minerals industry. Oil States has adapted its Merlin™ riser and connection system technology to support this rapidly developing industry of deepsea minerals gathering. Oil States’ President and Chief Executive Officer, Cindy B. Taylor, stated,“We are proud and honored to receive a Spotlight on New Technology® Award from OTC. Our Merlin™ Deepsea Mineral Riser System provides a robust, fast make-up, hands-free, automated system capable of withstanding extreme operating conditions...

GDS Holdings Limited Reports First Quarter 2021 Results

Written by Customer Service on May 19, 2021. Posted in Public Companies.

SHANGHAI, China, May 19, 2021 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2021. First Quarter 2021 Financial Highlights Net revenue increased by 37.5% year-over-year (“Y-o-Y”) to RMB1,706.0 million (US$260.4 million) in the first quarter of 2021 (1Q2020: RMB1,240.4 million). Service revenue increased by 38.3% Y-o-Y to RMB1,704.5 million (US$260.2 million) in the first quarter of 2021 (1Q2020: RMB1,232.6 million). Net loss was RMB278.7 million (US$42.5 million) in the first quarter of 2021, compared with a net loss of RMB92.0 million in the first quarter of 2020. Adjusted EBITDA (non-GAAP) increased by 43.0%...

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer

Written by Customer Service on May 19, 2021. Posted in Public Companies.

Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer Amcenestrant, an investigational oral selective estrogen receptor degrader (SERD), achieved an objective response rate of 34% and a clinical benefit rate of 74% in Phase 1 study (AMEERA-1) in combination with palbociclib Overall safety profile of amcenestrant with palbociclib is consistent with what was observed in monotherapy, without signs of significant cardiac or ocular side effects The Phase 3 combination study (AMEERA-5) of amcenestrant with palbociclib in the first-line setting was initiated in October 2020 and is successfully recruiting patients The pivotal study (AMEERA-3) of amcenestrant versus physician’s choice in locally advanced or metastatic estrogen receptor-positive (ER+) breast...

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Written by Customer Service on May 19, 2021. Posted in Public Companies.

Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as first line monotherapy in anti-C5 treatment-naïve patients with paroxysmal nocturnal hemoglobinuria Updated efficacy and safety results from pivotal ELARA trial of Kymriah® (tisagenlecleucel) in relapsed or refractory follicular lymphoma Data demonstrate Novartis innovation for patients and strength of its four therapeutic platforms: targeted therapies, radioligand...

Day: May 19, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice